| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/06/2009 | CA2713163A1 Galenic form for the oral transmucosal delivery of triptans |
| 08/06/2009 | CA2713075A1 Cationic sirnas, synthesis and use for interfering rna |
| 08/06/2009 | CA2713043A1 Substituted gamma lactams as therapeutic agents |
| 08/06/2009 | CA2712966A1 Marker for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | CA2712962A1 Thiazole derivative and use thereof as vap-1 inhibitor |
| 08/06/2009 | CA2712897A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| 08/06/2009 | CA2712888A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| 08/06/2009 | CA2712885A1 Substituted pyridazine derivatives which have histamine h3 antagonist activity |
| 08/06/2009 | CA2712856A1 Use of eicosapentaenoic acid and/or docosahexaenoic acid in women with endometriosis |
| 08/06/2009 | CA2712854A1 Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals |
| 08/06/2009 | CA2712724A1 Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency |
| 08/06/2009 | CA2712701A1 Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| 08/06/2009 | CA2712647A1 Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis |
| 08/06/2009 | CA2712553A1 Use of ibogamine congeners for treating obesity |
| 08/06/2009 | CA2712352A1 Dicycloazaalkane derivates, preparation processes and medical uses thereof |
| 08/06/2009 | CA2712339A1 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin |
| 08/06/2009 | CA2712095A1 Crystalline cinnamide compounds or salts thereof |
| 08/06/2009 | CA2711995A1 Novel n-(2-amino-phenyl)-amide derivatives |
| 08/06/2009 | CA2711774A1 Fentanyl-containing patch for external use |
| 08/06/2009 | CA2711759A1 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| 08/06/2009 | CA2711725A1 Synthesis of novel neamine derivatives and use thereof as antibacterial agents |
| 08/06/2009 | CA2711673A1 Pharmaceutical compositions for treating fatty liver disease |
| 08/06/2009 | CA2711575A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/06/2009 | CA2710929A1 Imidazopyrazines as protein kinase inhibitors |
| 08/06/2009 | CA2710838A1 Pharmaceutical compositions |
| 08/06/2009 | CA2706808A1 Composition for photodynamic skin treatment |
| 08/06/2009 | CA2698463A1 Therapeutic kinase modulators |
| 08/06/2009 | CA2652445A1 System and method for diagnosing and managing those at risk for cardiovascular disease |
| 08/05/2009 | EP2085783A1 Use of NGF inhibitors in breast cancer therapy |
| 08/05/2009 | EP2085780A2 Methods and products related to low molecular weight heparin |
| 08/05/2009 | EP2085478A1 A long QT syndrome gene which encodes KVLQT1 and its association with minK |
| 08/05/2009 | EP2085402A1 Phosphates of secondary alcohols |
| 08/05/2009 | EP2085400A1 Substituted heteroarylamide oxazepinopyrimidone derivatives |
| 08/05/2009 | EP2085399A1 substituted arylamide oxazepinopyrimidone derivatives |
| 08/05/2009 | EP2085398A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/05/2009 | EP2085397A1 Crystalline form of abacavir |
| 08/05/2009 | EP2085396A2 Novel crystalline forms of tiotropium bromide |
| 08/05/2009 | EP2085395A1 Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| 08/05/2009 | EP2085394A2 Metronidazole derivatives as antiparasitic agents |
| 08/05/2009 | EP2085391A2 Inhibitors of factor XA and other serine proteases involved in the coagulation cascade |
| 08/05/2009 | EP2085390A1 Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| 08/05/2009 | EP2085389A1 Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
| 08/05/2009 | EP2085388A1 Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
| 08/05/2009 | EP2085387A1 Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents |
| 08/05/2009 | EP2085386A2 Pyridinium and quinolinium derivatives as Choline kinase inhibitors |
| 08/05/2009 | EP2085383A1 Piperidine derivatives or salts thereof |
| 08/05/2009 | EP2085380A1 Process for production of 1-hydroxy-19-norcyclovitamin d derivative and intermediate for the production |
| 08/05/2009 | EP2085379A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 08/05/2009 | EP2085377A1 Novel salts of O-desmethyl-venlafaxine |
| 08/05/2009 | EP2085097A1 Highly water-dispersible powder and method of producing the same |
| 08/05/2009 | EP2085094A2 Application of aminopeptidases inhibitors and pharmaceutical preparations containing same |
| 08/05/2009 | EP2085090A2 Inhibitors of DNA immunostimulatory sequence activity |
| 08/05/2009 | EP2085089A1 Phospholipids Containing omega-3-Fatty Acids for the Treatment of Overweight, Obesity and Addictive Behavior |
| 08/05/2009 | EP2085088A1 Adhesive preparation |
| 08/05/2009 | EP2085087A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 08/05/2009 | EP2085086A2 Method for treating congestive heart failure or diabetic nephropathy |
| 08/05/2009 | EP2085085A1 The uses of the carboxy-amido-triazole compounds and salts thereof |
| 08/05/2009 | EP2085084A1 Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics |
| 08/05/2009 | EP2085083A1 Mixture of citric flavonoids to improve ruminal fermentation |
| 08/05/2009 | EP2085082A1 Treatment of cognitive decline |
| 08/05/2009 | EP2085081A1 3-(2-dimethyl amino methyl-cyclohexyl) phenol for treating polyneuropathic pain |
| 08/05/2009 | EP2085079A2 Process for stabilizing famotidine |
| 08/05/2009 | EP2085078A1 Controlled porosity osmotic pump tablet of high permeable drugs and the preparation method thereof |
| 08/05/2009 | EP2085076A1 Pharmaceutical composition in the form of coated microspheres for the modified release of a muscle relaxant and an nsaid |
| 08/05/2009 | EP2085075A1 Stable shaped particles of crystalline organic compounds |
| 08/05/2009 | EP2085074A1 Drug microparticles |
| 08/05/2009 | EP2085073A1 Drug microparticles |
| 08/05/2009 | EP2085072A1 Drug microparticles |
| 08/05/2009 | EP2085071A1 Orally or nasally administrable preparations containing epinephrine with improved characteristics |
| 08/05/2009 | EP2084175A1 Hcv nucleoside inhibitor |
| 08/05/2009 | EP2084173A1 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof |
| 08/05/2009 | EP2084172A1 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof |
| 08/05/2009 | EP2084163A2 Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 08/05/2009 | EP2084162A2 Bicyclic triazoles as protein kinase modulators |
| 08/05/2009 | EP2084161A1 Adenine derivatives as inhibitors of hsp90 for the treatment of cancer |
| 08/05/2009 | EP2084160A1 Hiv integrase inhibitors |
| 08/05/2009 | EP2084159A1 Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors |
| 08/05/2009 | EP2084157A1 Crystalline form of tiotropium bromide and urea |
| 08/05/2009 | EP2084155A1 Thiazole derivatives as kinase inhibitors |
| 08/05/2009 | EP2084154A1 Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders |
| 08/05/2009 | EP2084153A1 Thionucleosides and pharmaceutical applications |
| 08/05/2009 | EP2084152A2 Substituted 4-imidazoles |
| 08/05/2009 | EP2084151A1 Substituted dihydropyrazolones for treating cardiovascular and haematological diseases |
| 08/05/2009 | EP2084149A1 Organic compounds |
| 08/05/2009 | EP2084147A1 Heterocyclic fxr binding compounds |
| 08/05/2009 | EP2084146A1 Cyclic derivatives as modulators of chemokine receptor activity |
| 08/05/2009 | EP2084145A2 (s)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use |
| 08/05/2009 | EP2084143A1 Novel 1,4-benzothiepin-1,1 -dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof |
| 08/05/2009 | EP2084141A1 Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| 08/05/2009 | EP2084137A1 Process for the sulfinylation of a pyrazole derivative |
| 08/05/2009 | EP2084134A1 Chemical compounds |
| 08/05/2009 | EP2084133A2 Process for preparing crystalline aripiprazole |
| 08/05/2009 | EP2084132A1 Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate |
| 08/05/2009 | EP2084131A1 Indole and benzofuran 2-carboxamide derivatives |
| 08/05/2009 | EP2084127A1 Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
| 08/05/2009 | EP2084125A1 Aminobenzocycloheptene derivatives, methods for preparing the same and uses thereof in therapy |
| 08/05/2009 | EP2084124A1 Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
| 08/05/2009 | EP2083924A1 Method for treating skin by administering an agent that decreases gmcsf release from keratinocytes |
| 08/05/2009 | EP2083922A1 VR1 RECEPTOR LIGANDS AND µ OPIOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN |
| 08/05/2009 | EP2083921A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |